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Abstract
Background: Remote ischemic postconditioning (rIPostC) refers to the observation that repeated, short periods
of ischemia protect remote areas against tissue damage during and after prolonged ischemia. Based on previous
observations of a potential neuroprotective effect of rIPostC, the aim of this study is to evaluate whether repeated
rIPostC after an ischemic stroke can reduce infarct size, which could be translated to an improvement in clinical
outcomes.
Methods/design: We will enroll 200 ischemic stroke patients to daily rIPostC or sham conditioning during
hospitalization into a randomized single-blind placebo-controlled trial. The intervention consists of twice daily
exposure to four cycles of 5-min cuff inflation around the upper arm to > 20 mmHg above systolic blood
pressure (i.e., rIPostC) or 50 mmHg (i.e., control), followed by 5 minutes of deflation. The primary outcome is
infarct size, measured using an MRI diffusion-weighted image at the end of hospitalization. Secondary outcomes
include the Modified Rankin Scale, National Institutes of Health Stroke Scale, quality of life, and cardiovascular and
cerebrovascular morbidity and mortality. To explore possible underlying mechanisms of rIPostC, venous blood will be
sampled to assess biomarkers of inflammation and vascular health.
Discussion: Previous studies in animals and humans, using a single bout of remote ischemic conditioning, report a
potential effect of rIPostC in attenuating neural damage. Although repeated rIPostC has been investigated for
cardiovascular disease patients and preclinical stroke models, no previous study has explored the potential
physiological and clinical effects of repeatedly applying rIPostC during the hospitalization phase after a stroke.
Trial registration: Netherlands Trial Register, NTR6880. Registered on 8 December 2017.
Keywords: Stroke, Ischemia, Ischemic conditioning, Infarct size, Clinical outcome
Background
Ischemic stroke is the leading cause of disability in adults
worldwide and has the second highest mortality of all car-
diovascular diseases [1]. In particular, the intravenous and
endovascular treatment of ischemic stroke has markedly
improved survival and long-term functional outcomes [2–
4]. Unfortunately, a substantial number of stroke patients
still end up with a physical disability. This may in part be
because the therapeutic window to attenuate the detri-
mental impact of ischemic injury is limited to 6 hours
after the stroke. Currently, there are no subsequent treat-
ment options available [5], although some recent studies
have had promising results for intra-arterial therapy in
specific subgroups of stroke patients [6, 7]. Moreover,
acute revascularization might induce ischemia reperfusion
injury [8] and glutamatergic excitotoxicity [9], which could
lead to additional damage in the ischemic penumbra. This
highlights the need for innovative additional treatment op-
tions, which preferably would extend beyond the 6 hours
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post-stroke. Identification of such treatment options may
have a significant impact on the burden of stroke for indi-
vidual patients, their caregivers, health-care professionals,
and at the socioeconomic level.
A potential approach may be the application of remote
ischemic postconditioning (rIPostC). Remote ischemic
conditioning (RIC) consists of several cycles of brief pe-
riods (5 min) of limb ischemia followed by reperfusion,
which can be applied by inflating a simple blood pres-
sure cuff. This intervention subsequently confers protec-
tion against severe ischemia in remote organs in humans
[10–12]. Due to the unpredictability of stroke, applying
RIC before the event is not possible. However, similar
protective effects are present when RIC is applied during
or even after an ischemic insult [13], which is known as
rIPostC. Whilst the majority of studies have focused on
the protective effects of ischemic pre- and postcondi-
tioning on cardiac tissue [10–12, 14, 15], recently, sev-
eral studies have supported the ability of rIPostC to
reduce neural damage after reperfusion [8, 16–19], valid-
ating that rIPostC may have clinical potential for stroke
patients, with clinical trials showing promising results
[20, 21]. Additionally, Hess et al. postulated that, in
addition to the short-lasting benefits of a single bout of
conditioning, chronic benefits may be induced with re-
peated daily conditioning [18]. This has since been sup-
ported by preclinical studies in mice and rats [22, 23]
and further supported by evidence from clinical trials in
humans with favorable clinical outcomes for repeated
rIPostC in ischemic stroke patients [24, 25].
We, therefore, hypothesized that rIPostC during the
first few days following an ischemic stroke reduces in-
farct size. Since infarct size is strongly related to func-
tional recovery [26], repeated rIPostC may be a simple
and novel strategy to minimize the clinical impact of an
ischemic stroke. Importantly, rIPostC is virtually
cost-free, non-pharmacological, and non-invasive, and




The aim of this trial is to examine the effect of repeated
(twice daily) rIPostC during hospitalization on infarct
size and clinical outcomes in ischemic stroke patients. In
addition, we aim to explore the potential underlying (in-
flammatory) mechanisms for this effect of repeated
rIPostC.
Design
We will perform a randomized single-blind placebo-
controlled clinical trial at the Radboud University Med-
ical Centre (Radboudumc) in Nijmegen, the Netherlands.
The study has been approved by the relevant ethical
committee (CMO Arnhem-Nijmegen, registration num-
ber 2017–3711). This protocol has been registered with
the Netherlands Trial Register (NTR6880).
Patient population and randomization
Patients with an ischemic stroke who are being admitted
to the emergency room of the Radboudumc are eligible
for this study. Other inclusion criteria are: older than 18
years and a clinical diagnosis of an ischemic stroke
(established by a neurologist, based on the World Health
Organization criteria for stroke) [27]. Exclusion criteria
include: unstable vital signs, admitted more than 12
hours after onset of symptoms, upper extremity injury,
edema contra-indicating rIPostC, bilateral mastectomy,
or axillary lymph node dissection. Patients with
contra-indications for magnetic resonance imaging
(MRI; e.g., those with a pacemaker, vascular clips, coch-
lear implants, or other implanted metal objects) will also
be excluded because of the impossibility of assessing our
primary outcome. All patients will provide written in-
formed consent. For those patients who are not mentally
capable of signing informed consent in the acute setting,
oral assent will be obtained. This will allow the interven-
tion to start while providing an opportunity for informed
consent to be given when the patients or their caregivers
are capable of making a well-considered decision. Pa-
tients who receive a change in diagnosis after inclusion
will be excluded from the analysis of our primary out-
come (infarct size).
After informed consent or oral assent has been given,
randomization will be performed using a predefined table
generated by the computer program SealedEnvelope. Pa-
tients will be randomized in a 1:1 ratio to rIPostC or sham
conditioning by the coordinating investigator. Stratifica-
tion will be performed for treatment received (thrombec-
tomy, thrombolysis, or no revascularization treatment) to
ensure equal allocation of these subgroups to rIPostC and
sham conditioning.
Intervention: repeated remote ischemic postconditioning
A manual blood pressure cuff will be placed around the
upper arm after the diagnosis of an ischemic stroke. All
participants will receive four cycles of 5-min inflation of
the blood pressure cuff, followed by 5 minutes of reperfu-
sion. This procedure will be performed twice daily (morn-
ing and afternoon) during the hospitalization after the
ischemic stroke for a maximum of 4 days. The level of cuff
inflation differs between the groups. Cuff inflation in the
rIPostC-group is >20mmHg above systolic blood pres-
sure, mediating full blockage of the arterial inflow. Sub-
jects in the control group receive cuff inflation to 50
mmHg, which will not induce any ischemia. The interven-
tion will be administered by a trained researcher. Blood
pressure will be recorded before the intervention.
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Primary outcome measure
The primary outcome measure will be the infarct size on
day 4 after admission (or at discharge if discharge is be-
fore day 4), which will be compared between the inter-
vention and control groups. The infarct size will be
evaluated by diffusion-weighted MRI brain imaging
using a 1.5-tesla MRI scanner (Siemens® Avanto). The
infarct size will be annotated manually and analyzed on
a dedicated work station by a trained researcher under
the supervision of a neuroradiologist.
Secondary outcome measures
(1) The validated and frequently used Modified Rankin
Scale (mRS) [2, 28, 29] will be used to assess clinical out-
comes after 12 weeks. To assess clinical outcomes at the
end of hospitalization, the validated National Institutes
of Health Stroke Scale [30] will be used. Both scores are
calculated as standard after a stroke and will be assessed
by a clinical physician or nurse from the neurology
department.
After 12 months, we will also examine hospitalization,
recurrent (cerebro)vascular events, and mortality. These
data will be extracted from patient files at the
Radboudumc.
(2) To assess quality of life, participants will be asked to
fill out two questionnaires after 12 weeks and 1 year. The
first questionnaire is the Stroke-Specific Quality of Life
Scale (SSQoL), which is reliable and reproducible for
self-reported quality of life outcomes in stroke patients
[31]. The second questionnaire is the TOPICS-SF (The
Older Persons and Informal Caregivers Survey Short
Form), which is used for assessing patient-reported out-
come measures. The TOPICS-SF has been shown to be a
valid and feasible questionnaire for older patients [32, 33].
(3) Venous blood will be sampled during the first pres-
entation at the emergency department and at the end of
hospitalization to explore the impact of daily rIPostC on
vascular, immune, and anti-inflammatory pathways.
Whole blood will be spun down and serum will be stored
at −80 °C for future analysis. For further analysis of pos-
sible underlying mechanisms, urine will also be sampled
and stored at −80 °C at the end of hospitalization.
An overview of all outcomes and corresponding mea-
surements is presented in Fig. 1.
Sample size calculation
The sample size was estimated based on two trials [34,
35], which had a similar stroke population. Based on our
clinical experience, we expect that a difference of 15 cm3
in infarct size between the two randomized groups
should be considered as a clinically important difference.
From the two trials, we estimated a standard deviation
of 36 cm3. Based on α = 0.05 and power β = 0.80, we
calculated that we need n = 90 per study arm. To ac-
count for an expected drop-out rate of 10%, we will in-
clude 100 patients in each group. This group size is
comparable with other trials [20, 36] with the same
intervention (rIPostC) and primary outcome (infarct
size).
Statistical analyses
Data will be analyzed according to an intention-to-treat
analysis for all randomized patients. The primary out-
come (infarct size) will be analyzed as a continuous vari-
able using an independent t-test and presented with a
95% confidence interval for differences between both
groups. Based on observations in previous research [2,
35, 37], we expect infarct size to be normally distributed.
If the data are not normally distributed, a logarithmic
transformation can be used. If this procedure fails,
non-parametric alternatives will be used to analyze the
data.
To analyze the mRS score, the odds ratio for a shift in
the direction of a better outcome on the mRS will be
assessed in both groups [38]. This ratio will be estimated
with ordinal logistic regression and will be calculated for
all possible cut-off values on the mRS.
For all continuous endpoints (e.g., quality of life,
patient-reported outcomes, hospitalization, recurrent
cerebrovascular accidents, and mortality, inflammatory,
and vascular biomarkers), an independent t-test can be
used to evaluate differences between usual care and
rIPostC. We will consider the outcomes that are
assessed at different time points (quality of life and
patient-reported outcomes) as separate outcomes due to
the possibility that there will be missing data after 12
months. If these continuous outcomes are, contrary to
our expectations, not normally distributed, then a loga-
rithmic transformation or non-parametric alternatives
will be used.
Analyses will be done on the full data, and a
sub-analysis will be performed excluding the patients
who do not have a visible infarct on the MRI. Prior to
analyses, the extent of missing data on all secondary out-
comes will be evaluated and appropriate methods to
handle missing data will be determined (e.g., multiple
imputation). To ensure the analyses are blinded, all data
will be blinded prior to analysis by an independent re-
searcher. Full details of the analysis will be finalized in
an analysis plan before the database is locked.
Discussion
To our knowledge, this is one of the first clinical trials
to investigate the effect of rIPostC after a stroke. Two
previous studies have shown promising results for a sin-
gle bout of RIC after a stroke [20, 21] and several other
trials (registered under NCT02779712, NCT03045055,
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and NCT02189928 [36]) are currently being conducted
that investigate the effect of a single bout of rIPostC in
stroke patients. However, so far, no definitive conclusions
on the effect of this intervention have been reported in
this population. Our trial will study the effect of daily re-
peated rIPostC on both infarct size and clinical outcomes,
but also aims to achieve a better understanding of the pos-
sible physiological mechanisms underlying this effect.
The primary outcome for this trial will be the differ-
ence in infarct size between the intervention and control
groups. Infarct size in brain MRI scans was chosen be-
cause it can be assessed objectively. Moreover, infarct
size has been used as a primary outcome in animal stud-
ies that showed a positive effect of rIPostC on infarct
size [22, 39]. Diffusion-weighted imaging has been
chosen to analyze the MRI data because it allows for a
fast and reliable analysis of infarct size in the acute stage
and does not require the use of contrast medium, thus
minimizing patient burden.
We also aim to investigate clinical outcomes using the
frequently used and validated mRS [2, 28, 29]. Import-
antly, this study has not been powered for this secondary
outcome and, therefore, we may encounter challenges in
detecting a significant difference between study arms.
Nonetheless, infarct size has been reported to be a pre-
dictor for clinical outcomes in stroke patients [26] and
the mRS scores will be used in the power calculation of
a future clinical trial in which functional performance
will be a clinical outcome.
Finally, we aim to include 200 patients. With approxi-
mately 250 stroke patients being admitted to the Rad-
boudumc each year and with the eligibility criteria for
this trial being very broad, we expect to recruit a suffi-
cient number of patients during our recruitment period
of ~2.5 years. We will include all stable adult stroke pa-
tients with a clinically diagnosed stroke who do not have
contra-indications for an MRI or rIPostC and who are
able to provide written informed consent. Based on this
Fig. 1 Schedule of enrolment, interventions, and assessments according to the SPIRIT guidelines [40]. d day, w week, m month, Int intervention,
MRI magnetic resonance imaging, mRS Modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, rIPostC Remote ischemic
postconditioning, SSQoL Stroke-Specific Quality of Life, TOPICS-SF The Older Persons and Informal Caregivers Survey Short Form
Landman et al. Trials          (2019) 20:167 Page 4 of 6
nonrestrictive participant selection, we expect no prac-
tical problems in recruiting a sufficient number of pa-
tients. An important advantage of our approach is that
the results of our trial can be generalized to the larger
population of stroke patients.
Trial status
The first patient was randomized on 23 April 2018. At
the time of the first submission of this manuscript, three
patients had been recruited into the trial. Recruitment
will continue until the complete sample size is achieved,
which is expected to be in August 2020 at the latest.
Additional file
Additional file 1: SPIRIT checklist for the REPOST trial. (DOCX 61 kb)
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